11 results
The primary objective is to determine whether additional treatment with exenatide in patients with acute myocardial infarction and treated with primary PCI, leads to a more preserved left ventricular function, compared to placebo in addition to…
Overarching Aim: to detail the (mechanisms underlying the) actions of GLP-1RA and DPP-4i on the cardiovascular, renal and gastrointestinal system patients with T2DM. For the sake of clarity, we divide the study objectives into 3 parts:Primary…
Primary objective:To assess whether a single day infusion of the GLP-1 RA exenatide, as compared to placebo, reverses GC-induced impairment of glucose metabolism and beta-cell function in healthy males
In this study we will assess the effects of exenatide on cardiac metabolism and function in patients with T2DM and CHF. We will address the following hypothesis: exenatide improves global cardiac function in CHF patients with T2DM, by favorable…
The results of this study will give better insights in the role of ADMA in the development of systemic endothelial dysfunction.
The results of this study will give better insights in the role of ADMA in the development of systemicendothelial dysfunction and the relation with mild renal insufficiency.
Primary objective: to investigate the effect of treatment with the GLP-1ra exenatide on the awareness of and counterregulatory hormone responses to hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia. Secondary…
The purpose of the study is to investigate to what extent Exenatide MPF is tolerated.It will also be investigated how quickly and to what extent Exenatide, when administered as Exenatide MPF, is absorbed and eliminated from the body (this is called…
Primary objective:To investigate the separate and combined actions of the SGLT2 inhibitor dapagliflozin and GLP-1 receptor agonist exenatide on activity in central reward and satiety circuits in response to food related stimuli in obese patients…
-Evaluate the long-term safety and tolerability of apitegromab in patients with Type 2 and Type 3 SMA-Evaluate the long-term efficacy of apitegromab by assessing changes in motor function outcome measures at prespecified time points-Further evaluate…
Primary-Assess the efficacy of apitegromab compared with placebo using the HFMSE in patients 2 through 12 years oldKey secondary-Assess the efficacy of apitegromab compared with placebo based on the number of patients with clinical improvement in…